These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24369336)

  • 1. Renal amyloidosis after a short period since diagnosis of ileocolonic Crohn's disease.
    Karaahmet F; Akinci H; Hamamci M; Bahceci M; Coban S; Yuksel I
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):473-4. PubMed ID: 24369336
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic amyloidosis with Crohn's disease treated with infliximab.
    Park YK; Han DS; Eun CS
    Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease: case report and review of the literature.
    Pukitis A; Zake T; Groma V; Ostrovskis E; Skuja S; Pokrotnieks J
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):333-6. PubMed ID: 24078992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiximab for treatment of systemic amyloidosis associated with Crohn's disease.
    Said Y; Debbeche R; Hamzaoui L; Lounissi M; Trabelsi S; Bouzaidi S; Salem M; Abdelmoula L; Najjar T
    J Crohns Colitis; 2011 Apr; 5(2):171-2. PubMed ID: 21453891
    [No Abstract]   [Full Text] [Related]  

  • 5. Remicade approved for children with Crohn's disease.
    FDA Consum; 2006; 40(4):6. PubMed ID: 17245830
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with crohn's disease.
    Iizuka M; Sagara S; Etou T
    Inflamm Bowel Dis; 2011 Jul; 17(7):E67-8. PubMed ID: 21509909
    [No Abstract]   [Full Text] [Related]  

  • 7. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
    Meier J; Sturm A
    Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
    [No Abstract]   [Full Text] [Related]  

  • 9. Leptospira interrogans icterohaemorrhagiae in a patient with Crohn's disease.
    Katsanos KH; Katopodis KP; Kosmidou M; Siamopoulos KC; Tsianos EV
    Inflamm Bowel Dis; 2010 Nov; 16(11):1824-5. PubMed ID: 20186939
    [No Abstract]   [Full Text] [Related]  

  • 10. Infliximab in fistulizing Crohn's disease.
    Osterman MT; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid recovery of a rectovaginal fistula with infliximab in a patient with Crohn's disease.
    Hagiu C; Badea R; Serban A; Petrar S; Andreica V
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):329-32. PubMed ID: 20922201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M; Panes J; García V; Mañosa M; Esteve M; Merino O; Andreu M; Gutierrez A; Gomollón F; Cabriada JL; Montoro MA; Mendoza JL; Nos P; Gisbert JP
    J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor.
    Boscá MM; Pérez-Baylach CM; Solis MA; Antón R; Mayordomo E; Pons S; Mínguez M; Benages A
    Gut; 2006 Feb; 55(2):294-5. PubMed ID: 16407390
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab.
    Fidalgo C; Calado J; Cravo M
    BioDrugs; 2010 Dec; 24 Suppl 1():15-7. PubMed ID: 21175229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab treatment in a patient with Crohn's disease on haemodialysis.
    Kume K; Yamasaki M; Yoshikawa I; Harada M
    Colorectal Dis; 2011 Mar; 13(3):341. PubMed ID: 20082632
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn's disease.
    Tada Y; Ishihara S; Ito T; Matsui K; Sonoyama H; Oka A; Kusunoki R; Fukuba N; Mishima Y; Oshima N; Moriyama I; Yuki T; Kawashima K; Sato S; Adachi K; Ikeuchi H; Kinoshita Y
    Intern Med; 2013; 52(17):1899-902. PubMed ID: 23994979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: anti-TNF strategies in the treatment of Crohn's disease.
    Rutgeerts PJ; Targan SR
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():1. PubMed ID: 10597332
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence for the clinical use of infliximab in Crohn's disease.
    Turner SM; Probert CS
    Rom J Gastroenterol; 2003 Mar; 12(1):2-5. PubMed ID: 12673372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.